(Reuters) – China has several new vaccine applicants who oppose late-stage coronavirus.
Below is a summary of its efforts to develop vaccines.
Four of the seven vaccines in the world in the third of the tests are from China.
Two of the applicants are from the National Biotech Group of China (CNBG), a unit of the National Pharmaceutical Group of China Public Pharmaceuticals (Sinopharm).
Sinovac Biotech is running as the third candidate named CoronaVac, while CanSino Biologics is running with the Military Research Unit of the Academy of Military Medical Sciences at Ad5-nCoV.
Argentina, Peru, Morocco, Bahrain and the United Arab Emirates have the legal CNBG to conduct Phase 3 trials. It is not known whether the company’s two candidate vaccines will be tested in those countries.
Indonesia and Brazil are in phase 3 sinovac Trials CoronaVac, while Bangladesh aims to conduct a complex clinical trial for the experimental vaccine.
Pakistan, Saudi Arabia and Russia have agreed to conduct Phase 3 trials on the CanSino candidate, while Mexico has signed a quick agreement with the Chinese company for a complex level trial.
HOW ARE COVID-19 EXPERIMENTAL VACCINES USED IN CHINA?
China has been administering experimental coronavirus vaccines to groups facing high infection risks such as medical workers since July under an “emergency use” programme.
The authorities would likely modestly expand the emergency use programme to check and prevent outbreaks during autumn and winter.
China did not specify how many other people were vaccinated or which product was administered.
Prior to the program’s official launch in July, the Chinese military approved the use of the CanSino vaccine in June, while state media reported in June that workers at state-owned traveling enterprises were allowed to take one of two candidate vaccines that are being developed through CNBG.
Compiled through Roxanne Liu in Beijing and Miyoung Kim in Singapore; Editing through Robert Birsel
All quotes were delayed for at least 15 minutes. See here for a complete list of transactions and delays.
© 2020 Reuters. All rights are reserved.